After treating a tumor with chemotherapy and radiotherapy, cells known as senescent cells can appear. These are cells that do ...

Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...

Much of our knowledge of the protein PD-1, a leading cancer treatment target, comes from studies in mice. In a comprehensive assessment of PD-1, researchers have found that PD-1 in mice is ...

Researchers have discovered that mouse PD-1 is significantly weaker than human PD-1, calling into question their reliability ...

About LM-299 LM-299 is an investigational bispecific antibody targeting both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). This innovative therapeutic ...

A novel molecular tool developed by a Lehigh University professor of biological sciences is enabling scientists to precisely ...

Volrustomig is under clinical development by AstraZeneca and currently in Phase II for Malignant Neoplasms. According to GlobalData, Phase II drugs for Malignant Neoplasms does not have sufficient ...

Studies of living participants and postmortem brains confirm that gene expansion is a promising target for HD prevention ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.

Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA. Caenorhabditis elegans drp-1 and fis-2 Regulate Distinct Cell-Death Execution Pathways Downstream of ced-3 and ...